These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21411799)

  • 21. Mycophenolate mofetil and oral ulcerations.
    Apostolou T; Tsagalis G; Koutroubas G; Hadjiconstantinou V; Drakopoulos S
    Transplantation; 2004 Jun; 77(12):1911-2. PubMed ID: 15223919
    [No Abstract]   [Full Text] [Related]  

  • 22. Orogenital ulcers in a liver transplant recipient: discerning between mycophenolate-mofetil-induced complication and Behcet's disease.
    Savas N; Sevmis S; Karakayali H; Yilmaz U; Haberal M
    Clin Transplant; 2009; 23(2):147-9. PubMed ID: 19191805
    [No Abstract]   [Full Text] [Related]  

  • 23. Mycophenolate mofetil-related pancolitis in a kidney transplant recipient.
    Hamouda M; Mahmoudi H; Skhiri H; Elmay M
    Exp Clin Transplant; 2012 Oct; 10(5):501-5. PubMed ID: 22554227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience.
    Kirklin JK; Bourge RC; Naftel DC; Morrow WR; Deierhoi MH; Kauffman RS; White-Williams C; Nomberg RI; Holman WL; Smith DC
    J Heart Lung Transplant; 1994; 13(3):444-50. PubMed ID: 8061021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary induction with mycophenolate mofetil and corticosteroids in a liver transplant recipient with hepatorenal syndrome.
    Carr RR; Yoshida EM; Chung SW; Partovi N
    Ann Pharmacother; 1998 Jan; 32(1):45-8. PubMed ID: 9475819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic effect of mycophenolate mofetil on early outcomes of living donor kidney transplantation.
    Samadzadeh B; Alemi M; Heidarnejadiyan J; Torkamanasadi F
    Iran J Kidney Dis; 2012 Jan; 6(1):63-8. PubMed ID: 22218122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.
    Fulton B; Markham A
    Drugs; 1996 Feb; 51(2):278-98. PubMed ID: 8808168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review.
    Su VCh; Greanya ED; Ensom MH
    Ann Pharmacother; 2011 Feb; 45(2):248-57. PubMed ID: 21304036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mycophenolate mofetil-induced mouth ulcers in a kidney transplant patient: Case report and literature review.
    Plana-Pla A; Solé LC; Garcia AB; Valdemoros RL
    Nefrologia (Engl Ed); 2019; 39(1):80-83. PubMed ID: 30082101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
    Nashan B; Suwelack B; Ivens K; Arns W; Lhotta K; Bourbigot B; Budde K; Fischer W; Pietruck F;
    Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generic formulation of mycophenolate mofetil (Myfenax) in de novo renal transplant recipients: results of 12-month observation.
    Rutkowski B; Bzoma B; Dębska-Ślizień A; Chamienia A
    Transplant Proc; 2014 Oct; 46(8):2683-8. PubMed ID: 25380894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group.
    Transplantation; 1999 Aug; 68(3):391-6. PubMed ID: 10459543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pure Red Cell Aplasia in a Renal Transplant Recipient: Case Report and Review of the Literature.
    Nagib AM; Gheith OA; Zahab MA; Balaha MA; Elserwey NA; Sobhy I; Nair P; Al-Otaibi T
    Exp Clin Transplant; 2022 Mar; 20(Suppl 1):136-139. PubMed ID: 35384824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation.
    Hale MD; Nicholls AJ; Bullingham RE; Hené R; Hoitsma A; Squifflet JP; Weimar W; Vanrenterghem Y; Van de Woude FJ; Verpooten GA
    Clin Pharmacol Ther; 1998 Dec; 64(6):672-83. PubMed ID: 9871432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of pure red-cell aplasia with cyclosporine in a renal transplant patient.
    Yildirim R; Bilen Y; Keles M; Uyanik A; Gokbulut P; Aydinli B
    Exp Clin Transplant; 2013 Feb; 11(1):63-5. PubMed ID: 22891934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.